



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

JPL/SEC/RESU-NOT

Date: November 14th, 2013

The National Stock Exchange of India Limited
Kind Attn. Mr. Hari K - President
Exchange Plaza, Bandra-Kurla Complex
Bandra E), Mumbai - 400 051.
FAX 022-26598237-38

The Bombay Stock Exchange Limited
Pherozebhoj Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
FAX 022-22723121, 22722037, 22723719, 22722041

SUB: UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30.09.2013 & LIMITED REVIEW

Dear Sir,

In terms of Clause 41 of the listing agreement we are sending herewith unaudited financial results (provisional), for the quarter ended 30th September, 2013 and Limited Review.

Thanking you.

Yours faithfully,
for **JAGSONPAL PHARMACEUTICALS LIMITED**



R K KAPOOR
COMPLIANCE OFFICER CUM COMPANY SECRETARY

Encl. : As above.



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

JAGSONPAL PHARMACEUTICALS LIMITED Unaudited Financial Results for the Quarter ended 30.09.2013

Particulars	3 months ended 30.09.2013 Unaudited	3 months ended 30.06.2013 Unaudited	3 months ended 30.09.2012 Unaudited	6 Months ended 30.09.2013 Unaudited	6 Months ended 30.09.2012 Unaudited	12 Months Ended 31.03.2013 Audited
Rs. in lacs						
1 Income from operations						
a Net sales/Income from Operations (Net of excise duty)	3678.97	3807.88	4178.33	7486.85	7901.02	16646.45
b Other Operating Income						
Total Income from operations (net)	3678.97	3807.88	4178.33	7486.85	7901.02	16646.45
2 Expenses						
a Cost of materials consumed	954.13	2002.68	1437.22	2956.81	3088.60	7091.87
b Purchases of stock-in-trade	276.84	147.09	308.25	423.93	762.50	1069.51
c Changes in inventories of finished goods, work in progress and	553.87	-33.59	332.82	520.28	-28.72	454.84
d Employee benefits expenses	972.98	874.89	963.73	1847.87	1830.79	3725.46
e Depreciation and amortisation expense	71.02	69.11	69.92	140.13	135.10	270.76
f Other expenses	728.71	611.86	866.03	1340.57	1781.55	3299.35
Total expenses	3557.55	3672.04	3977.97	7229.59	7569.82	15911.79
3 Profit from Operations before Other Income, Finance Cost and						
Exceptional items (1-2)	121.42	135.84	200.36	257.26	331.20	734.66
4 Other Income				0.00	0.00	32.31
5 Profit from ordinary activities before finance cost and	121.42	135.84	200.36	257.26	331.20	766.97
Exceptional items (3+4)						
6 Finance Cost	111.83	134.98	125.42	246.81	241.20	513.35
7 Profit from ordinary activities after finance cost but before	9.59	0.86	74.94	10.45	90.00	253.62
Exceptional Items (5-6)						
8 Exceptional Items						
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	9.59	0.86	74.94	10.45	90.00	253.62
10 Tax expense	9.00	0.50	33.00	9.50	48.00	70.36
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	0.59	0.36	41.94	0.95	42.00	183.26
12 Extraordinary Items (net of tax expense Rs. lacs)						
13 Net Profit(+)/Loss(-) for the period(11-12)	0.59	0.36	41.94	0.95	42.00	183.26
14 Share of profit/(Loss) of associates						
15 Minority interest						
16 Net Profit/(Loss) after taxes, minority interest and share of	0.59	0.36	41.94	0.95	42.00	183.26
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet						
of pr. Accounting yr						7239.49
19.i Earnings Per Share (before extraordinary items)						
a. Basic (Rs.)	0.00	0.00	0.16	0.00	0.16	0.70
b. Diluted (Rs.)	0.00	0.00	0.16	0.00	0.16	0.70
19.ii Earnings Per Share (after extraordinary items)						
a. Basic (Rs.)	0.00	0.00	0.16	0.00	0.16	0.70
b. Diluted (Rs.)	0.00	0.00	0.16	0.00	0.16	0.70

A PARTICULARS OF SHAREHOLDING

1 Public Shareholding						
- Number of shares	8962360	8962360	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%	34.21%	34.21%
2 Promoter and promoter group shareholding						
A Pledged / encumbered						
- Number of shares						
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)						
- Percentage of shares (as a % of the total share capital of the Company)						



Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone : 0091-95129-2275952, 2275953
 Factory : Plot No. 14, 15, 16, 55, 56, 57, Sector-5, IIE, Pant Nagar, Rudrapur (U.S. Nagar) - 263153 Uttara Khand



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

B Non - encumbered						
- Number of shares	17235640	17235640	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%	65.79%	65.79%

B INVESTOR COMPLAINTS

Pending at the beginning of the quarter	0
Received during the quarter	13
Disposed of during the quarter	13
Remaining unresolved at the end of the quarter	0

Notes

1. The Unaudited Financial Results for the Quarter ended 30.9.2013 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 14.11.2013
2. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
3. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
4. Previous year figures have been regrouped / rearranged wherever necessary.



Place : New Delhi
Date : 14.11.2013

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre,
Babar Road, New Delhi - 110 001
Ph. (O) : 23413486
E-mail : sureshsethi62@yahoo.com

Limited review report for Jagsonpal Pharmaceuticals Limited

To whom it may concern

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.09.2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards² and other recognised accounting practices and policies has not disclosed the

information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : New Delhi
Date : 14.11.2013

for P. P. THUKRAL & CO.,
Chartered Accountants


SURESH SETHI
PARTNER

F.R. No. 000632 N
Membership no. 89318